awmsg logo



cariprazine (Reagila®)


Reference No. 731

Publication date:
29/11/2017


Appraisal information

cariprazine (Reagila®) 1.5 mg hard capsule
cariprazine (Reagila®) 3 mg hard capsule
cariprazine (Reagila®) 4.5 mg hard capsule
cariprazine (Reagila®) 6 mg hard capsule


Company: Gideon Richter
BNF category: Central nervous system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 28/11/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, cariprazine (Reagila®) cannot be endorsed for use within NHS Wales for the treatment of schizophrenia in adult patients.
Statement of Advice (SOA)
Download